| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10918945 | Radiotherapy and Oncology | 2012 | 6 Pages |
Abstract
Patients undergoing high dose thoracic radiotherapy combined with chemotherapy or cetuximab reported a gradual deterioration in functioning, dyspnoea and fatigue, while treatment related side effects were transient. Radiotherapy with concurrent cetuximab had less negative impact on HRQL than concurrent chemoradiation.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Andreas Hallqvist, Bengt Bergman, Jan Nyman,